Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 03 2021 - 5:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of March 2021
Commission
File Number: 001-38773
CHINA
SXT PHARMACEUTICALS, INC.
(Translation
of registrant’s name into English)
178
Taidong Rd North, Taizhou
Jiangsu,
China
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual
report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document
that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant
is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the
home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a
press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing
a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
EXPLANATORY
NOTE
In
connection with the 2021 Annual Meeting of Shareholders of China SXT Pharmaceuticals, Inc., a British Virgin Islands company (the
“Company”), the Company hereby furnishes the following documents:
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CHINA
SXT PHARMACEUTICAL, INC.
|
|
|
|
|
By:
|
/s/
Feng Zhou
|
|
|
Feng
Zhou
|
|
|
Chief
Executive Officer
|
Date:
March 2, 2021
2
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Jul 2024 to Aug 2024
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Aug 2023 to Aug 2024